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Enhancing Response in the Cardiac
Resynchronization Therapy Patient
The 3B Perspective—Bench, Bits, and Bedside
Angelo Auricchio, MD, PHD,a Frits W. Prinzen, PHDb
ABSTRACT
Cardiac resynchronization therapy (CRT) is an established nonpharmacological treatment for patients with heart failure
(HF), reduced left ventricular (LV) ejection fraction, and a wide QRS complex. Although the therapy was developed
30 years ago and approved by the Food and Drug Administration in 2001, attempts to improve it have never stopped.
Such improvements have been facilitated by combining knowledge from bench (basic science), bits (computer modeling),
and bedside (clinical studies); these issues are addressed in the present review. Improvements include better
patient selection, positioning of the LV lead, pacing from multiple sites, and optimization of atrioventricular and
ventriculoventricular intervals. Overall, patterns of electrocardiographic and echocardiographic (strain) signals appear
to be more useful for patient selection than timing intervals (QRS duration, time-to-peak shortening). Quadripolar
leads have signiﬁcantly improved CRT outcome due to increased electrical and mechanical lead performance (avoiding
phrenic nerve stimulation and improving lead stability), but also thanks to the ﬂexibility offered by the novel leads to
avoid in-scar pacing. The beneﬁt of multiple site stimulation over optimal conventional biventricular pacing seems small
and is awaiting evidence from large trials. There is rapidly growing interest in merging imaging information to guide
positioning of the LV lead in late activated regions without scar and in LV lead positions other than the epicardial
coronary veins (LV endocardium, His bundle, LV septum). All these developments look promising but await further
clinical validation. Finally, computer modeling is rapidly becoming important in understanding the substrate for CRT, in
improving and assisting patient selection, as well as in guiding therapy planning. (J Am Coll Cardiol EP 2017;3:1203–19)
© 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
H eart failure (HF) is a signiﬁcant healthproblem that affects nearly 20 millionpeople worldwide, with a projected 25%
increase in prevalence by 2030. Related expenditures
are expected to more than double by the same period
(1). Despite signiﬁcant advances in pharmacological
therapy, morbidity and mortality remain high (2).
Ventricular conduction disturbance, most commonly
left bundle branch block (LBBB), is present in approx-
imately one-third of HF patients, and leads to
loss of synchrony of contraction of the ventricles.
Consequently, these patients are at higher risk of HF
hospitalization and death.
In 1987, Dr. Morton Mower ﬁled a patent applica-
tion for the concept of “biventricular pacing” after a
pre-determined atrioventricular (AV) interval explic-
itly aimed at HF failure treatment. This concept, later
termed cardiac resynchronization therapy (CRT), is
currently an established nonpharmacological treat-
ment for patients with HF, reduced left ventricular
(LV) ejection fraction, and a wide QRS complex (3,4).
It has been revolutionary for patients with advanced
HF whose only previous option was cardiac trans-
plantation, and it is now a realistic option for
patients with mild HF (3,4). CRT remains the only
therapy for HF that simultaneously improves cardiac
function and functional capacity, reduces hospitali-
zation, and prolongs survival (Figure 1). The large
range of beneﬁts among patients, spanning from
complete normalization of ventricular volume and
ejection fraction to a complete lack of beneﬁt,
has triggered signiﬁcant research activities to
de-convolute the biological and mechanistic aspects
for CRT inefﬁcacy, some of which are discussed in
the present review and are illustrated in Figure 2.
From the beginning, research in the ﬁeld of CRT has
been characterized by a bedside-to-bench and back
again approach, whereas during the last decade,
computer models have provided rapidly increasing
additional insights. Therefore, this review discusses
the combination of “bench, bits, and bedside” (which
we named “the 3B perspective”) by considering
that the combination of these 3 factors may bring the
ﬁeld forward.
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PATHOBIOLOGY OF CRT
Dyssynchrony and its correction by CRT induces a
wide range of changes beyond the direct electrical
and mechanical effects, many of which are unique to
the disease. The seminal work by the Baltimore group
showed that dyssynchronous HF is characterized by
maladaptive remodeling processes at all levels,
ranging from the genome to the proteome, tran-
scriptome, metabolome, and is visible at the cellular
level, translating to the phenotype (9). Altogether,
these abnormalities have been referred as
dyssynchronopathy (9). In dyssynchronous HF, most
of the defects are speciﬁc to early- or late-activated
myocardial territories, including processes like
hypertrophy and related expression of microRNAs
(10). CRT can correct most of these defects by mech-
anisms that are still not completely elucidated.
Although little information is available on the tis-
sue changes in human dyssynchronous hearts,
several clinical trials showed that patients with LBBB
in the control arms had a worse prognosis than pa-
tients with otherwise similar degrees of HF but no
LBBB (11). In contrast, once treated by CRT, the LBBB
patients had an improved outcome beyond that of
other patients, supporting an idea that originated
from animal experiments on extensive cellular and
molecular recovery. Clinical data were limited to re-
ductions in cavity dimensions and levels of circu-
lating plasma markers of inﬂammation, such as
apoptotic signaling of ﬁbrosis. Some studies indicated
that, upon turning CRT off after several months,
intrinsic QRS duration was reduced (12), which might
be explained by the reduction in ﬁbrosis or modiﬁ-
cation in myocardial tissue architecture, gap junction
expression, myocardial hypertrophy and/or smaller
ventricular chambers. Clearly, more information on
myocardial changes during clinical application of CRT
would be welcome, if only because understanding
these changes could also be beneﬁcial to the treat-
ment of other pathologies.
PATIENT SELECTION:
DEVELOPING VIEWS ON USE OF
ELECTROCARDIOGRAPHIC CRITERIA
QRS duration and a LBBB morphology of the QRS
complex are currently considered the most reliable
biomarkers for selecting candidates for CRT. According
to clinical practice guidelines by all scientiﬁc societies
in cardiology, CRT eligibility includes a QRS duration
of >120 ms and LBBB morphology (3,4). Clinical prac-
tice guidelines may recommend CRT in patients with a
QRS duration of <150 ms only when a clear LBBB
morphology of the QRS complex is diagnosed
(3,4). However, electrocardiography (ECG)
criteria to classify LBBB signiﬁcantly differ
among scientiﬁc organizations, investigators,
trials, and guidelines, which may pose uncer-
tainty in meta-analytical analysis and com-
parison of outcomes. Notably, ECG deﬁnitions
for LBBB have never been designed to predict
response to CRT.
The challenge usually pertains to the
detection of QRS slurring and notching to
identify LBBB. There is no standard deﬁnition
of QRS notch and slur patterns in modern
quantitative ECG; this is likely because
deﬁnitions are difﬁcult to apply manually
by clinicians because physicians rely on
small amplitude and duration measurements.
Measuring and interpreting the QRS
complex from a standard 12-lead ECG is a
lengthy and tedious process, especially if the
patient has an underlying disease (e.g., pre-
vious myocardial infarction or myocardial
hypertrophy), which may further alter the
morphology and duration of QRS. Although
the QRS delineation and duration are believed
to be usually easier to be determined than notching
and slurring, recent reports have indicated large
interobserver and intraobserver variability in manual
reading (13), as well as limited accuracy and precision
of automated measurements of QRS duration among
ECGs (14). The difference could exceed the level of
10 to 15 ms, which might be considered clinically sig-
niﬁcant for qualifying a patient for CRT or for
providing a class of recommendation for CRT (14).
Interestingly, there is limited literature on the corre-
lation of a speciﬁc morphological marker associated
with intraventricular conduction disturbance, LBBB,
or right bundle branch block (RBBB) with clinical
in vivo measurements of intracardiac activation times.
Also, the threshold of 120 ms that indicates an
abnormal QRS duration was established based on a
pattern recognition that compared dogs with humans,
not on objective measurements in humans (15).
Although most patients treated with CRT have a
LBBB QRS morphology, since the introduction of CRT
into clinical practice, a growing number of patients
with RBBB QRS morphology or intraventricular con-
duction abnormalities have also been treated. A recent
review reported that an average of 18% of all treated
CRT patients had RBBB, with a variable proportion
ranging from 5% to 26% (16). Thus, these patients
represent a sizeable subgroup in need of adjunct
therapies on top of the best pharmacological therapy.
The available evidence indicates that straightforward
AB BR E V I A T I O N S
AND ACRONYM S
AV = atrioventricular
BiV = biventricular
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
CRT = cardiac
resynchronization therapy
ECG = electrocardiography
ECGi = electrocardiographic
imaging
HF = heart failure
HR = hazard ratio
LBBB = left bundle branch
block
LV = left ventricle
LV dP/dtmax = ﬁrst derivative
of left ventricular pressure
RBBB = right bundle branch
block
RV = right ventricle
VCG = vectorcardiography
VV = ventriculo-ventricular
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application of CRT in patients with RBBB should be
discouraged (16). However, in vivo mapping data and
in silico simulation indicates that there is a subset of
patients with RBBB who may beneﬁt from CRT; these
patients are characterized by a QRS morphology on
limb leads that resemble a LBBB and show delayed LV
activation, particularly of the LV free wall (17). Thus,
an individualized treatment strategy in RBBB is of
utmost importance and should be used based on the
presence of LV and right ventricular (RV) dyssyn-
chrony demonstrated either by advanced echocar-
diographic techniques (18) or by the surface ECG (17).
Admittedly, the treatment options for these patients
with RBBB, previously proposed by us, have been
mechanistically developed (12), and may require
conﬁrmation in larger prospective studies.
Therefore, due to all of the previously indicated
limitations of surface ECG in precisely deﬁning
bundle branch block and reliable prediction of CRT
response, other ECG-derived indexes may be worth
considering.
FIGURE 2 Key Elements of Modern Use of CRT in Heart Failure Patients
AV ¼ atrioventricular; VV ¼ ventriculo-ventricular; other abbreviations as in Figure 1.
FIGURE 1 Compilation of the Various Effects of CRT
(A) Acute hemodynamic effect as reported by the PATH-CHF study (adapted from Auricchio A, et al. [5]). (B) Reverse remodeling as described
in REVERSE study (adapted from Linde C, et al. [6]). (C) Reduction in hospitalization for heart failure as shown by MADIT-CRT (adapted from
Moss A, et al. [7]). (D) Reduction in mortality as reported by the RAFT trial (adapted from Tang et al., [8]). CRT ¼ cardiac resynchronization
therapy; CI ¼ conﬁdence interval; ICD ¼ implantable cardioverter-deﬁbrillator; LV dP/dtmax ¼ ﬁrst derivative of left ventricular pressure;
LVESVi ¼ left ventricular end-systolic volume index.
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BEYOND CONVENTIONAL 12-LEAD ECG. Of all the
characteristics of a LBBB-like conduction abnormal-
ity, delayed activation of the LV is likely crucial for
a heart to be amenable to CRT (19). This inferred
abnormality is supported by studies that showed that
a greater delay in time from onset of the QRS com-
plex to local LV activation at the LV stimulation site
(Q-LV) was associated with a greater likelihood of
beneﬁt from CRT (20). The most accurate way to
determine late LV activation is to directly measure it
(21), which requires an invasive procedure. Although
it can be performed during a CRT implantation pro-
cedure (20), the decision whether to implant a device
should be made in advance. ECG imaging (ECGi)
provides a valuable noninvasive alternative to direct
measurement (22). ECGi provides high-resolution
noninvasive electrical mapping of the epicardial
electrical activation, and requires a computed tomo-
graphic scan and positioning of a few hundred elec-
trodes on the body surface. A recent study provided
extensive validation of this technique in animal
hearts with pacing-induced dyssynchrony. This
study pointed to the important role of a proper
spatio-temporal approach that considers character-
istics of neighboring electrograms (23). Ploux et al.
(22) showed that the mean electrical delay between
the RV and LV provides good prediction of CRT
response. A recent, simpler alternative was pre-
sented, in which an ECG belt with 53 electrodes was
used to characterize the electrical heterogeneity of
the ventricles (24).
A different approach may be the use of vectorcar-
diography (VCG), synthesized from the regular
12-lead ECG (25). A VCG-derived area of the QRS
complex (QRS area) strongly predicted late activation
of the LV, even in RBBB (26). QRS area was shown to
be a good predictor of echocardiographic CRT
response, performing at least as well as LBBB and
outperforming both QRS duration >150 ms and LBBB
(27). Other studies also showed that T-wave area
and the sum of QRS and T-wave area provided good
prediction of CRT response (28). The fact that
these measures can be obtained using routine ECG
measurements makes them good candidates for
widespread use soon.
MECHANICAL MARKERS OF DYSSYNCHRONY
The working mechanism of CRT is complex and still
not completely understood. Part of this complexity
comes from the fact that CRT is primarily designed for
correction of an electric substrate (originating from
conduction disorders), but it exerts its effects mainly
through correction of mechanical inefﬁciency.
Because of the heterogeneous overall response in
accordingly selected patients, mechanical dyssyn-
chrony has been proposed as an additive selection
criterion.
Although simple echocardiographic markers like
apical rocking, septal ﬂash, and interventricular me-
chanical dyssynchrony appear valuable in identifying
patients who would most likely beneﬁt from CRT (29),
more sophisticated echocardiographic indexes of
mechanical dyssynchrony were tested in the early
2000s. Large randomized trials that used different
echocardiographic indexes consistently reported
disappointing results. A good example of a negative
study in the ﬁeld is the EchoCRT study. This study
selected patients with narrow (<130 ms) QRS com-
plexes and mechanical dyssynchrony that were
identiﬁed by interventricular mechanical delay
and/or longitudinal strain. Patients who received
biventricular (BiV) pacing actually showed a worse
outcome, including signiﬁcantly higher mortality
compared with patients in the control group (30).
The subgroup of patients with low global longitudinal
strain showed a particularly poor clinical outcome,
which indicated the harmful effect of improperly
TABLE 1 Commercially Available Pacing Algorithms for Single-Lead Left Ventricular Multipoint Pacing and Possible Pacing Conﬁgurations
Feature Name
Boston Scientiﬁc
MultiSite Pacing
St. Jude
Multipoint Pacing
Medtronic
Multiple Point Pacing
Biotronik
MultiPole Pacing
CE Mark Status Established 1Q 2017 Approved Approved Approved
Pacing Vectors Available 17 10 5 12
LVa - LVb Timing Offset Independent cathodes
0–100 ms
Independent cathodes
5–80 ms offsets
Tied cathodes, no offsets Independent cathodes
0–50 ms
Automatic Programming
Recommendation
Yes
SmartVector algorithm
automatically
recommends settings
Yes
Options for choosing based
on RV-LV or widest
spacing
None for MPP Unknown
Pacing Conﬁgurations Bi-V
LV only
Bi-V Bi-V
LV only
Bi-V
CE ¼ European Commission; Bi-V ¼ biventricular; LV ¼ left ventricular; MPP ¼ MultiPoint Pacing; RV ¼ right ventricular.
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applied CRT in combination with poor myocardial
contractile function (31).
A more promising picture appeared for strain-based
parameters of mechanical dyssynchrony applied in
patients with a wider (>130 ms) QRS complex. Several
large, recent observational studies that used advanced
echocardiographic measurements, including speckle
trackingderived indexes, showed an improvement in
the prediction of echocardiographic CRT response on
top of QRS duration and QRS morphology when they
analyzed time-to-peak values (18,32,33). Even better
predictions were achieved when considering the
regional differences in morphology of strain curves
(34,35) (see the following on Computer Modeling).
Such regional differences in morphology of strain
curves are helpful to distinguish LBBB-like conduc-
tion abnormalities that are amenable to correction by
CRT from ventricular conduction disturbance-like
ones, which, in contrast, are unlikely to respond to
CRT. The same concept applies to patients with RBBB,
in whom the presence of regional differences of strain
curves resembling a LBBB-like pattern most likely
point to a positive response to CRT (18).
DEVELOPMENTS IN DELIVERY OF CRT: TARGETED LEAD
PLACEMENT, MULTISITE PACING, AND MULTIPOINT
PACING. During the last decade, improved physio-
pathological knowledge and signiﬁcant technological
advancement have resulted in LV placement guided
by multimodality imaging, more appropriate selec-
tion of LV epicardial pacing sites via the coronary
sinus, possible multiple site pacing, and multipoint
LV pacing. According to common terminology,
multisite pacing is obtained by using 2 leads in 2
different coronary veins or 2 separate RV sites,
whereas multipoint pacing is delivered using multi-
ple electrodes on a single LV lead (Table 1). The
concept of multisitemultipoint pacing is based on
the hypothesis that pacing at multiple locations
within the ventricles electrically engages a larger
ventricular mass and will therefore improve cardiac
resynchronization.
TARGETED LEAD PLACEMENT. Beside the substrate
for resynchronization, a primary point of interest is
the site of LV pacing, because this is likely to deter-
mine the degree of resynchronization. The presence,
location, and burden of myocardial scar and the
position of the LV lead with respect to these regions
are key determinants in CRT response. Implantation
of a LV lead in an area of myocardial scar may be
associated with slow conduction and block, resulting
in less hemodynamic improvement and poor clinical
outcome.
A few published studies investigated whether a
greater response to CRT could be achieved through
targeted delivery of LV leads to late-activated seg-
ments free of scar. The STARTER (Speckle Tracking
Assisted Resynchronization Therapy for Electrode
Region) study, performed with the 17-segment
echocardiographic model, indicated good CRT
response when the LV lead was truly concordant
with or in any of the 8 LV segments adjacent to the
last-activated segment (36). In this study, segments
with echocardiographic evidence of scarring were
excluded from analysis. Similarly, in the TARGET
(Targeted Left Ventricular Lead Placement to guide
Cardiac Resynchronization Therapy) study, consid-
erable beneﬁt from CRT was derived from positioning
the LV lead away from regions with low strain, which
suggested scarring (37). Pacing in a scarred region was
associated with a 6-fold increased risk of cardiovas-
cular death or combined cardiovascular death and
hospitalization for HF compared with pacing in re-
gions with no scarring (38). Therefore, current evi-
dence points more to the importance of avoiding LV
lead positioning in a scarred region than positioning
it in the latest activated region, and eventually to a
more systematic assessment of the presence, loca-
tion, and extension of myocardial scar by different
cardiac imaging techniques.
Further studies investigated a more advanced use
of imaging for road mapping of LV lead placement.
Bakos et al. (39) showed the feasibility of using a
combination of echocardiographic speckle tracking
and cardiac magnetic resonance (CMR) to guide
placement of the LV lead to prescribed targets. Pro-
cedural success, deﬁned as lead delivery to the pre-
scribed or immediately adjacent segment, was 95%.
More recently, Behar et al. (40) tested the feasibility
of a purpose-built integrated software platform to
process, analyze, and overlay CMR data in real-time
within a hybrid X-CMR environment to guide LV
lead implantation. These authors contemporaneously
used gold standard myocardial imaging to avoid scar
regions while targeting late activating segments,
thereby permitting imaging-guided LV lead implan-
tation in a single procedure. Despite the best-in-class
imaging and lead technology for guiding quadripolar
LV lead implantation, in 4 patients (28%), a CMR-
deﬁned target segment (based upon avoiding scar
and targeting a late mechanical activated segment)
could not be reached due to lack of an appropriate
coronary vein. This resulted in the placement of
a quadripolar LV lead adjacent to or in the scar. This
observation strongly suggests that further improve-
ment in alternative lead positioning is needed
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(see Emerging Technologies for Resynchronizing the
Heart).
MULTISITE CRT. The concept of triple-site pacing is
interesting, but one of the limitations is that this
pacing modality has been evaluated only in small
studies with soft endpoints, with the exception of the
recent study by Providencia et al. which reported
all-cause mortality and frequency of ventricular ar-
rhythmias (41). Moreover, these studies are hetero-
geneous as far as patient selection (nonresponder to
CRT vs. de novo patients), intrinsic rhythm (sinus
rhythm vs. atrial ﬁbrillation), and strategy for placing
double LV leads is concerned; thus, comparing their
results is somewhat challenging.
The TRIP-HF (Triple Resynchronization in Paced
Heart Failure Patients) trial compared conventional
CRT to BiV stimulation with 1 RV and 2 LV leads in
42 patients (42). This study showed a modest but
signiﬁcant improvement in LV ejection fraction and
LV end-systolic volume, whereas there was no
clinical beneﬁt of triple-site pacing over BiV pacing.
Lenarczyk et al. (43) performed a randomized trial in
44 patients and showed that after 3 months of CRT,
triple-site pacing (double left–single right pacing site)
was associated with a larger improvement in New
York Heart Association functional class, an increase in
oxygen consumption, and an increase in the 6-min
walking distance than conventional CRT. The ejec-
tion fraction was also higher, and intraventricular
synchrony was smaller in the triple-site pacing group
than in the conventional CRT group. Rogers et al. (44)
investigated 43 CRT patients in a double-blind
crossover trial. Pacing leads were positioned in the
RV apex and a lateral coronary sinus branch, with a
third ventricular lead implanted in a further lateral
coronary sinus branch in 23 patients and in the high
RV septum in 20 patients. Devices were programmed
in a randomized order to 4 pre-determined pacing
conﬁgurations: conventional BiV, triventricular,
dual-site and single-site left BiV, or RV pacing for a
3-month period with clinical and echo assessment at
the end of each period. Compared with BiV pacing,
triventricular pacing resulted in signiﬁcant improve-
ments in the 6-min walking distance (451  112 m vs.
425  119 m; p < 0.008), quality of life (32  19 vs.
38  24; p < 0.036), LV end-systolic volume (158 
79 ml vs. 168  76 ml; p < 0.05), and ejection fraction
(30  8% vs. 27  8%; p < 0.05). The most recent
study by Providencia et al. (41) is a single-center,
propensity score–matched study that compared the
long-term clinical outcomes of 34 patients implanted
with triventricular devices and BiV devices.
Triventricular-treated patients, compared with
BiV-treated patients, presented with a trend for
shorter battery longevity. Incidence of lead dislodg-
ment, device-related infection, and refractory
phrenic nerve capture was comparable in the 2
groups. All-cause mortality and need for heart trans-
plantation was lower in the triventricular-treated
group compared with conventional CRT. In contrast,
episodes of ventricular arrhythmia that required
implantable cardioverter-deﬁbrillator intervention
occurred more frequently in the BiV group versus the
triventricular group. This latter observation was in
line with the ﬁndings reported by Ogano et al. (45),
who showed a reduction of ventricular arrhythmias
that required appropriate therapies in triple-site
pacing compared with conventional CRT.
In summary, studies on pacing using multiple leads
on the RV or LV showed that it is feasible, with an
implantation success rate of approximately 85% to
95%. However, the overall implantation duration and
ﬂuoroscopic exposure might be longer than for con-
ventional CRT (43,44). Furthermore, the statistical
power of these studies is limited, and there is
currently not enough evidence to consider this pacing
modality as a ﬁrst-line therapy. Further prospective
clinical investigations are needed, with a clear evalu-
ation of the clinical beneﬁt and adverse events. The
rate of complications of 2 LV or RV pacing deliveries
have to be addressed in large trials that include lead
extraction-related issues, as does the impact of
decreased battery longevity. The currently available
complication rate with dual-vein LV pacing cannot
be generalized to other centers because centers un-
dertaking multisite pacing are usually high-volume
centers that report high success rates. There are 3
currently ongoing randomized, prospectively
designed, controlled trials (TRIUMPH CRT [Triple-site
Bi-Ventricular Stimulation in the Optimization of CRT;
NCT02350842], STRIVE HF [Standard Care Versus Tri-
Ventricular Pacing in Heart Failure; NCT02529410],
and Efﬁcacy and Safety of Multisite Cardiac
Resynchronization Therapy; NCT01966016). These are
feasibility studies that are assessing the improvement
in echocardiography parameters with triventricular
devices. Finally, although preliminary small studies
have shown interesting results with triple-site pacing,
clinicians should consider that the present clinical
comparator is no longer represented by conventional
CRT with a bipolar LV lead. In contrast, delivery of
modern CRT is based on multipolar leads connected to
a device capable of multipoint LV pacing using
sophisticated AV and ventriculo-ventricular (VV)
automatic programming algorithms (see section on
Multipoint CRT).
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MULTIPOINT CRT. In contrast to multisite pacing,
multipoint pacing has been made easily achievable by
development of a LV quadripolar lead and by the
concurrent development of CRT devices that are
capable of multiple electrical outputs that allow
different pacing vectors and timing delays between
LV pacing sites (Table 1). The use of a quadripolar lead
has already improved patient outcome and even
survival compared with a conventional bipolar LV
pacing lead due to fewer requirements for lead
replacement and elimination of phrenic nerve stim-
ulation (46,47). Transvenous procedural success with
novel quadripolar lead design is currently achieved in
up to 98% of cases. The use of a quadripolar lead that
enables dual LV site pacing (multivector pacing
conﬁguration) is associated with a lower risk of de-
activation (hazard ratio [HR]: 0.62; 95% conﬁdence
interval [CI]: 0.46 to 0.84; p < 0.002), replacement
(HR: 0.67; 95% CI: 0.55 to 0.83; p < 0.001), and death
(HR: 0.77; 95% CI: 0.69 to 0.86; p < 0.001).
Several studies suggested that multipoint pacing
(i.e., multivector pacing), all or not combined with
additional timing delays among different LV pacing
sites, might create additional beneﬁts compared with
traditional dual-site LV pacing. Acute hemodynamic
studies showed a signiﬁcant but small increment of
ﬁrst derivative of LV pressure (LV dP/dtmax) (by 2%
to 5% points) and stroke volume (by w5%) (48,49).
Small studies also showed a moderately better
echocardiographic and clinical response (50,51).
Further support for the beneﬁt is being investigated
in larger multicenter trials.
The MPP (MultiPoint Pacing) trial was a prospec-
tive, randomized, double-blind, controlled study to
evaluate the safety and efﬁcacy of CRT using a
quadripolar lead for multipoint pacing compared with
standard Bi-V pacing. Standard Bi-V pacing was
activated at implantation. Then, at 3 months post-
implantation, patients in whom the echocardio-
graphic parameters during MPP were equal or better
than during BiV pacing were randomized (1:1) to
either an MPP or BiV arm. Preliminary results indi-
cated that the primary safety endpoint was met with a
93.2% freedom from system-related complications.
The primary efﬁcacy endpoint was met by demon-
strating noninferiority of the response rate in the MPP
technology group compared with the BiV pacing
group at 9 months compared with 3 months.
Additional analyses demonstrated the ability of
multipoint technology to achieve an 87% response
rate in patients with optimal program settings (52).
Data that somewhat contradict those of the
aforementioned studies came from the iSPOT (Left
Ventricular Multispot Pacing for CRT) study. This
study compared the acute hemodynamic response of
the MPP study by using 3 electrodes on a quadripolar
lead compared with conventional BiV pacing (53).
Patients with LBBB underwent an acute hemodynamic
FIGURE 3 Effect of Patient and Pacing Site Selection on Effect Size of CRT
Data from the iSPOT study: the acute change in LV dP/dtmax between patients ranged between approximately 0% and approximately 60%,
whereas differences in change of LV dP/dtmax within a patient varied only by approximately 10%. Dis, Mid and Prox indicate biventricular pacing
using the distal, mid, or proximal sites on the quadripolar LV lead, whereas Multispot indicates pacing from all sites together. Abbreviations
as in Figure 1. Adapted from iSPOT (Left Ventricular Multispot Pacing for CRT) study (53), courtesy of Richard Cornelussen, Medtronic.
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study to determine the percentage change in
LV þdP/dtmax using a solid experimental design with
repeated (4 times) measurements at 5 different AV
delays. The percentage change in LV þdP/dtmax for
pacing of all of the 3 electrodes together was not
signiﬁcantly superior to any conventional BiV pacing
conﬁguration (Figure 3). Notably, there was a large
interpatient variability, with acute hemodynamic
responses ranging from approximately zero to þ60%
(patients 11 and 17, respectively) (Figure 3). However,
the difference in response among different pacing
sites was usually approximately 10%. This indicated
that patient selection was a more important determi-
nant of CRT response than (epicardial) LV lead posi-
tioning and number of pacing sites. The authors
concluded that, in patients with LBBB, MultiSPOT LV
pacing demonstrated comparable improvement in
contractility to the best conventional BiV pacing. The
reasons for the conﬂicting outcomes between the
iSPOT and other observational MPP studies, as well as
the MPP randomized study, might be found in the use
of different pacing vectors, the use of delays between
stimulation of different leads, and inclusion of AV
optimization in the iSPOT study. Additional statistical
bias in favor of multipoint pacing might be created by
the comparison of the best of several multipoint
pacing options versus a single conventional BiV pac-
ing setting. Thus, at present, the clinical value of any
multiple site pacing mode is still not entirely clear.
Finally, the fact that stimulating additional pacing
electrodes reduces device battery longevity should be
taken into consideration.
EMERGING TECHNOLOGIES FOR
RESYNCHRONIZING THE HEART:
ENDOCARDIAL PACING, TRANSSEPTAL PACING,
AND HIS BUNDLE PACING
The common denominators for emerging technolo-
gies for resynchronizing the heart aim at creating
activation patterns that are more physiological than
transvenous CRT; they do not aim at positioning the
lead in the latest activated region (Figure 4).
LV endocardial pacing has been proposed and has
been shown to be superior to conventional LV epicar-
dial pacing in the CRT setting in computer simulations
(54) and preclinical experiments (55,56). In various
canine LBBB models, superiority has been shown in
electrical resynchronization and acute hemodynamic
response (55,56). However, clinical studies showed
less reproducible differences. Derval et al. (57) was not
able to show signiﬁcantly better hemodynamic
FIGURE 4 Illustration of the Novel Pacing Approaches in CRT
(Left) Illustration of the 4 novel pacing approaches in CRT: 1. His bundle pacing, 2. LV endocardial pacing, 3. LV septal pacing, 4. Wireless pacing in the LV endocardium.
The fast conduction layer along the right ventricular and LV endocardium is depicted in orange and the Purkinje system is depicted in yellow. (Right) (A) Proposed
mechanism of the beneﬁt of His bundle pacing in the left bundle branch block (LBBB). The His bundle the ﬁbers for the right bundle branch(RBB) and LBB are
longitudinally dissociated so that in case of (B) proximal block, pacing in the His bundle can capture ﬁbers in the LBB. (C) This option is likely not beneﬁcial in
case of distal block. AVN ¼ atrioventricular node; HB ¼ His bundle; LAF ¼ left anterior fascicle; LPF ¼ left posterior fascicle; other abbreviation as in Figure 1. Adapted
from Teng et al. (65).
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response between pacing in the endocardial position
and immediately below the position of the coronary
sinus lead, although in each patient there was an
endocardial position that resulted in superior
improvement in pump function. Similarly, Spragg
et al. (58) found that endocardial pacing tended to be
superior to epicardial pacing in patients with ischemic
cardiomyopathy, but that the location of optimal LV
endocardial pacing varied among patients. Shetty et al.
(59) showed that LV endocardial pacing was superior
to epicardial pacing and that it performed at least as
well as CRT using multiple- or single-quadripolar
epicardial leads. Although conceptually promising,
practical implementation of long-term endocardial
CRT using conventional pacing leads is still problem-
atic, because currently leads placed in the LV cavity
require anticoagulation and show signiﬁcant
dislodgement. Despite long-term anticoagulation
therapy, the risk of stroke was substantial in the
ALSYNC (Alternate Site Cardiac Resynchronization)
study (60). ALSYNC evaluated the feasibility and
safety of LV endocardial pacing using a market-
released pacing lead implanted via a single pectoral
access by a novel atrial transseptal lead delivery sys-
tem. This study observed 14 transient ischemic attacks
(n ¼ 9, 6.8%), 5 nondisabling strokes (n ¼ 5, 3.8%), and
23 deaths (17.4%).
A promising novel approach may be wireless pac-
ing. Auricchio et al. (61), in a cohort of 17 patients,
showed the feasibility of providing endocardial
stimulation for CRT with a leadless, wireless tech-
nology. The more recent SELECT-LV (Safety and
Performance of Electrodes Implanted in the Left
Ventricle) study extended the data of this wireless
CRT approach, which resulted in a population of pa-
tients in whom conventional CRT failed. This study
showed an improvement in the clinical composite
score in 85% of patients, and a positive echocardio-
graphic response (reduction in left ventricular end-
systolic volume >15%) in 52% of patients at
6 months (12). These clinical outcomes compared
quite favorably with the clinical and structural im-
provements observed in conventional CRT trials.
His bundle pacing is a somewhat surprising option
to create resynchronization. The option can only be
effective if the bundle branch block is proximal,
which ﬁts with older studies that suggested that
ﬁbers of the right and left bundle branch might
already be divided inside the AV node (62) (Figure 4,
right panel). Depending on the nature of the LBBB, a
completely narrow QRS may be achieved by direct His
pacing. In the best option, direct His pacing is
achieved with low stimulation strengths, but if the
lead is not positioned inside the His bundle, the
virtual pacing electrode may capture the conduction
distally when the pacing output is high. Direct His
bundle pacing in CRT candidates has been recently
proposed and clinically tested in small patient cohort
studies as summarized by Upadhyay and Tung (63)
and Sharma et al. (64). Overall, there is a relatively
consistent beneﬁt with His-paced therapy. The 2
largest single-center case series of His bundle pacing
for CRT-eligible patients have been published by
Teng et al. (65) and by Ajijola et al. (66). Electrical
resynchronization via His bundle pacing was consis-
tently achieved in approximately 70% of patients who
presented with bundle branch block with CRT
indication. Interestingly, in nearly all patients, QRS
narrowing was demonstrated by nonselective His
capture, which resulted in an improvement in LV
ejection fraction, reduction in size of the LV, and
improvement in New York Heart Association func-
tional class at least as much as during BiV pacing.
Transseptal LV endocardial pacing is the most
recent development to pace LV. In this approach,
the LV lead is introduced into the RV and subse-
quently advanced through the interventricular
septum to reach the LV side of the septum (Figure 4).
This approach likely avoids any coagulation
problems, because there is no contact between the
electrode and blood in the LV cavity. Studies in
animals have shown that LV septum pacing yields LV
pump function and contractile coordination that
closely approximates that during normal ventricular
conduction and is signiﬁcantly better than that dur-
ing RV septal pacing, even in the chronic setting (67).
Recently, Maﬁ-Rad et al. (68) demonstrated that
permanent implantation of a pacing lead with an
extended helix in the LV septum using a transvenous
approach through the interventricular septum is
feasible and safe, at least in a small group of patients.
In these patients with sick sinus disease, LV septal
pacing reduced electric dyssynchrony and preserved
LV pump function compared with RV septal and RV
apex pacing. Electric and mechanical lead properties
of this prototype lead remained stable during
6-month follow-up. Notably, LV septal pacing may
avoid deterioration of LV function due to long-term
RV pacing in patients with bradycardia, but data
from animal studies suggest that it might also be an
alternative to BiV pacing (69).
NOVEL PACING ALGORITHMS FOR
AUTOMATIC SELECTION OF
ATRIOVENTRICULAR AND VV DELAY
Since the early days of CRT, appropriate selection of
AV delay and VV timing has been considered an
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important factor to improve stroke volume. Several
studies assessed the efﬁcacy of ECG algorithms,
echocardiography, or invasive assessments to deter-
mine ideal settings of AV delay and VV timing. Past
clinical trials most commonly used a so-called “static
programming approach” for AV delay and VV timing
optimization (i.e., early assessment of each timing
followed by infrequent adjustments over follow-up).
This programming strategy was the result of the
technological limitation in repeatedly evaluating AV
delay and VV timing. As result, an electrogram-based
algorithm and echocardiography to determine
optimal AV activation did not demonstrate clinical
superiority for the endpoint of LV end-systolic volume
(70,71). In contrast, recent controlled randomized
studies, the RESPOND-CRT (Clinical Trial of the
Sonrtip Lead and Automatic AV-VV Optimization) and
the AdaptivCRT (aCRT) algorithm (Medtronic, Inc.,
Mounds View, Minnesota), using a so-called “dynamic
programming approach,” suggested signiﬁcant
beneﬁt of patient-speciﬁc continuous optimization of
AV delay and VV timing, and a paced chamber (72,73).
The RESPOND-CRT study was a prospective, ran-
domized, double-blinded, multicenter, noninferiority
trial. Patients were randomized in a 2:1 fashion to
receive weekly, automatic CRT optimization with a
SonR contractility sensor (LivaNova, Paris, France)
versus an echo-guided optimization of AV and VV
timings (72). The SonR contractility sensor records
endocardial acceleration that correlates strongly with
LV dP/dtmax, a measure of cardiac contractility. The
primary efﬁcacy endpoint was the rate of clinical
response (patients alive, without adjudicated
HF-related events, with improvement in New York
Heart Association functional class or quality of life) at
12 months. The study randomized 998 patients.
Response rate was 75.0% in the SonR group versus
70.4% in the Echo group (mean difference: 4.6%; 95%
CI: 1.4% to 10.6%; p < 0.001 for a noninferiority
margin of 10.0%). At an overall mean follow-up of 548
days, SonR was associated with a 35% risk reduction
in HF hospitalization (HR: 0.65; 95% CI: 0.46 to 0.92;
log-rank p < 0.01).
The AdaptivCRT algorithm automatically adjusts
AV and VV delays on the basis of frequent evaluation
of the patient’s underlying intrinsic AV conduction
(74). Speciﬁcally, the algorithm provides LV-only
pacing synchronized to a spontaneous RV activation
when intrinsic AV conduction is normal or BiV pacing
when AV conduction is prolonged. The Adaptive CRT
clinical trial demonstrated that this novel algorithm
for delivering CRT was at least as effective as
protocol-driven echocardiographic optimization. The
time to ﬁrst HF admission was found to be similar for
aCRT patients and patients who underwent tradi-
tional echocardiographic optimization. Recently,
Starling et al. (75) showed that for HF hospitaliza-
tions, the 30-day readmission rate was 19.1% (17 of 89
patients) in the aCRT group and 35.7% (15 of 42
patients) in the Echo group (odds ratio: 0.41; 95% CI:
0.19 to 0.86; p < 0.02). For all-cause hospitalization,
the 30-day readmission rate was 14.8% (35 of 237
patients) in the aCRT group compared with 24.8%
(39 of 157 patients) in the Echo group (odds ratio:
0.54; 95% CI: 0.31 to 0.94; p < 0.03). The risk of
readmission after HF or all-cause index hospitaliza-
tion with aCRT was also signiﬁcantly reduced beyond
30 days. These results emphasized that use of the
aCRT algorithm was associated with a signiﬁcant
reduction in the probability of a 30-day readmission
after both HF and all-cause hospitalizations.
Finally, recent dog experiments showed the
potential to calculate VCGs from nonpaced leads in the
heart and to use the area of the determined QRS
complex to optimize AV and VV delay (76). The
smallest QRS area coincided with the setting, which
resulted in the best hemodynamic effect. This idea
was based on data that AV delays result in the smallest
QRS area on the body surface and that VCG coincides
with the best hemodynamic effect of CRT in patients
(77). This opens the possibility of using this biomarker
for continuous and ambulatory optimization.
ASSESSMENT OF
RESIDUAL MECHANICAL DYSSYNCHRONY
Restoration of more uniform distribution of LV
myocardial strain is an expected effect of CRT,
which is associated with improvement in LV function
and survival (78). Data on patterns of residual
myocardial dyssynchrony after CRT are limited.
An echocardiographic subanalysis of MADIT-CRT (78)
and subsequently by Tayal et al. (79) demonstrated a
signiﬁcant association between changes inmechanical
dyssynchrony in patients treated with CRT and the
occurrence of serious ventricular arrhythmias. Pa-
tients with new-onset dyssynchrony or persistent
dyssynchrony after CRT showed a poor prognosis even
after controlling for other known baseline predictors.
These ﬁndings indicate that more attention to the
change in mechanical contraction after CRT may
further improve the beneﬁt of CRT for patients.
COMPUTER MODEL-ASSISTED PATIENT
SELECTION AND CRT APPLICATION
Computer models can contribute in several ways to
improve clinical practice: better understanding of
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mechanisms of disease and therapy; better interpre-
tation of diagnostic measurements; and altogether
better planning of the therapy in the individual
patient by virtual delivery of therapy. Suchmodels can
also be used to improve the design of clinical trials.
Currently, there are even developments to create co-
horts of virtual patients for performing clinical trials in
silico (80). The ﬁeld of CRT is ideal for applying
FIGURE 5 Discrimination Between an Electromechanical and Nonelectrical Substrates of Mechanical Dyssynchrony
Simulated substrates of mechanical discoordination, created by the CircAdapt model. (A) An electromechanical LBBB substrate is simulated as a
septal-to-free wall gradient in activation delay. (B) A nonelectrical hypocontractility substrate simulated as a septal-to-free wall gradient in
contractility. (C) A nonelectrical scar substrate simulated by adding a septal-to-free wall gradient in passive stiffness to the hypocontractility
substrate is shown in B. All 3 substrates caused peak-to-peak radial strain delay, but the pattern of mechanical discoordination differs
considerably between the substrates. Peak septal (yellow arrow) and posterior (purple arrow) radial strains were used to quantify peak-to-
peak radial strain delay (black double-headed arrows). AVC ¼ aortic valve closure; AVO ¼ aortic valve opening; LV ¼ left ventricle; RV ¼ right
ventricle; other abbreviation as in Figure 4. Reproduced with permission from Lumens et al. (33).
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CENTRAL ILLUSTRATION Possible, in Part Future, Applications of Computer Models in CRT
Auricchio, A. et al. J Am Coll Cardiol EP. 2017;3(11):1203–19.
(Upper panel) The concept of the 3B-perspective. (Middle panel) Various diagnostic tools for better stratiﬁcation of cardiac resynchronization
therapy (CRT) patients, ranging from standard 12-lead electrocardiogram (ECG) to vectorcardiography (VCG), speckle tracking strains and late
enhancement-cardiac magnetic resonance (LE-CMR). (Bottom panel) Feeding a computer model with patient-speciﬁc diagnostic data can
provide patient-speciﬁc “ﬁngerprints” of cardiac electromechanics. This may help in better diagnosis and understanding of the mechanism of
disease, better understanding of diagnostic signals under baseline conditions, and may lead to better therapy planning and evaluation of novel
therapy options.
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computer models because conceptual integration of
all electrophysiological, contractile, and circulatory
properties of a patient are too complex for the human
brain. However, these models may be appropriately
handled by high-performing computers and sophisti-
cated mathematical algorithms that are capable of
delivering simulations in a clinical usable timing.
Computer models of the dyssynchronous heart
range from relatively simple 2-dimensional models
of cardiac contraction and hemodynamics (81) to
highly advanced 3-dimensional models that contain
ﬁber orientation, molecular properties of ion chan-
nels, myocardial contraction, and body surface ECG
(82–85). A good example of model-improved insight
in disease mechanism and diagnosis is that of
understanding of septal wall motion abnormalities,
known as septal ﬂash and septal rebound stretch
(33,81). In the past, it was debated whether these
paradoxical motions were caused by a transseptal
pressure gradient or by early septal contraction. By
varying myocardial and hemodynamic properties in
computer models, it could be demonstrated that the
slow and late contraction of the LV lateral wall were
the key determinants of the septal wall motion
abnormality. These models also showed that time to
peak strain is not a reliable estimate of true (model-
imposed) dyssynchrony, but that indexes of strain
patterns (e.g., septal rebound stretch and systolic
stretch index) might be better predictors of CRT
response (33,86,87). This was further supported by a
recent study from this group, which showed that
heterogeneity in electrical activation, contractility,
and stiffness could all lead to high values of time-to-
peak shortening, but with different strain patterns
(Figure 5). The Circadapt model also predicted that
the slope and intercept of the relation between time
of onset of electrical activation and peak shortening
characterized myocardial stiffness and contractility,
respectively (88).
Electrophysiological models have been used
to construct impulse conduction throughout the
ventricles based on the body surface ECG and
position of the heart in the chest of the patient (85)
or animal (89). In the latter animal study, strains
were also calculated, as well as the beneﬁt of CRT.
Patient-speciﬁc modeling of the effect of CRT in
such detailed models was established in studies
that had few patients (90). Such patient-speciﬁc
modeling has been achieved in hundreds of
patients using the simpler and mathematically faster
CircAdapt model (33,34).
With respect to application of resynchronization
therapy, model studies provided understanding as to
why LV pacing could be equivalent to BiV pacing
(33), to what extent patients with RBBB could
beneﬁt from CRT (16), or why endocardial CRT could
be superior to conventional epicardial CRT (50), and
ﬁnally, under what conditions MPP could improve
acute hemodynamic beneﬁt compared with conven-
tional BiV pacing (91). The ultimate goal for the
application of modeling for CRT would be to develop
a full model of the heart of an individual patient in a
way that does not disturb clinical workﬂow, to plan
the best position for the pacing leads, and to test the
effect of CRT ahead of implantation of the device
(Figure 5, Central Illustration). For the simpler
models, this might be just around the corner,
whereas routine clinical application of a more
complex fully coupled electromechanical model
might last another decade.
CONCLUSIONS
After decades of clinical use, CRT can be considered
an established therapy. Despite that, there are still
multiple open questions to be addressed that shall
further improve the proportion of patients who
respond to CRT. Progress in better understanding
the profound relationship between electrical and
mechanical disorder in HF patients with ventricular
conduction abnormalities is of paramount impor-
tance. In addition, the use of the most advanced
computer modeling should help in providing mecha-
nistic insights into CRT efﬁcacy, which coupled to
machine learning, might certainly help in solving
complicated problems with big data by identifying
interaction patterns among variables.
ADDRESS FOR CORRESPONDENCE: Dr. Angelo Auric-
chio, Division of Cardiology, Fondazione Cardiocentro
Ticino, Via Tesserete 48, 6900 Lugano, Switzerland.
E-mail: angelo.auricchio@cardiocentro.org.
RE F E RENCE S
1. Heidenreich PA, Albert NM, Allen LA, et al.
Forecasting the impact of heart failure in theUnited
States: a policy statement from the American Heart
Association. Circ Heart Fail 2013;6:606–19.
2. Benjamin EJ, Blaha MJ, Chiuve SE, et al.,
American Heart Association Statistics Committee
and Stroke Statistics Subcommittee. Heart Disease
and Stroke Statistics-2017 Update: A Report From
the American Heart Association. Circulation 2017;
135:e146–603.
3. Ponikowski P, Voors AA, Anker SD, et al. 2016
ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure: the Task Force for
the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology
(ESC) developed with the special contribution of
the Heart Failure Association (HFA) of the ESC. Eur
Heart J 2016;37:2129–200.
Auricchio and Prinzen J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 3 , N O . 1 1 , 2 0 1 7
The 3B Perspective in CRT N O V E M B E R 2 0 1 7 : 1 2 0 3 – 1 9
1216
4. Yancy CW, Jessup M, Bozkurt B, et al. 2017
ACC/AHA/HFSA Focused Update of the 2013
ACCF/AHA Guideline for the Management of Heart
Failure: A Report of the American College of
Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines and the Heart Fail-
ure Society of America. J Am Coll Cardiol 2017;70:
776–803.
5. Auricchio A, Stellbrink C, Sack S, et al., for the
Pacing Therapies in Congestive Heart Failure
(PATH-CHF) Study Group. Long-term clinical
effect of hemodynamically optimized cardiac
resynchronization therapy in patients with heart
failure and ventricular conduction delay. J Am Coll
Cardiol 2002;39:2026–33.
6. Linde C, Gold MR, Abraham WT, et al., for the
REsynchronization reVErses Remodeling in Sys-
tolic left vEntricular dysfunction Study Group.
Long-term impact of cardiac resynchronization
therapy in mild heart failure: 5-year results from
the REsynchronization reVErses Remodeling in
Systolic left vEntricular dysfunction (REVERSE)
study. Eur Heart J 2013;34:2592–9.
7. Moss AJ, Hall WJ, Cannom DS, et al., for the
MADIT-CRT Trial Investigators. Cardiac-resynch-
ronization therapy for the prevention of heart
failure events. N Engl J Med 2009;361:1329–38.
8. Tang AS, Wells GA, Talajic M, et al., for the
Resynchronization-Deﬁbrillation for Ambulatory
Heart Failure Trial Investigators. Cardiac-resynch-
ronization therapy for mild-to-moderate heart
failure. N Engl J Med 2010;363:2385–95.
9. Kirk JA, Kass DA. Cellular and molecular aspects
of dyssynchrony and resynchronization. Heart Fail
Clin 2017;13:29–41.
10. van Middendorp LB, Kuiper M, Munts C, et al.
Local microRNA-133a downregulation is associ-
ated with hypertrophy in the dyssynchronous
heart. ESC Heart Fail 2017;4:241–51.
11. Zareba W, Klein H, Cygankiewicz I, et al.,
MADIT-CRT Investigators. Effectiveness of cardiac
resynchronization therapy by QRS morphology in
the Multicenter Automatic Deﬁbrillator Implanta-
tion Trial-Cardiac Resynchronization Therapy
(MADIT-CRT). Circulation 2011;123:1061–72.
12. Reddy VY, Miller MA, Neuzil P, et al. Cardiac
resynchronization therapy with wireless left ven-
tricular endocardial pacing: the SELECT-LV study.
J Am Coll Cardiol 2017;69:2119–29.
13. Tomlinson DR, Bashir Y, Betts TR, Rajappan K.
Accuracy of manual QRS duration assessment: its
importance in patient selection for cardiac
resynchronization and implantable cardioverter
deﬁbrillator therapy. Europace 2009;11:638–42.
14. Vancura V, Wichterle D, Ulc I, Smíd J,
Brabec M, Zárybnická M, Rokyta R. The variability
of automated QRS duration measurement. Euro-
pace 2017;19:636–43.
15. Strauss DG, Selvester RH, Wagner GS. Deﬁning
left bundle branch block in the era of cardiac
resynchronization therapy. Am J Cardiol 2011;107:
927–34.
16. Auricchio A, Lumens J, Prinzen FW. Does car-
diac resynchronization therapy beneﬁt patients
with right bundle branch block: cardiac resynch-
ronization therapy has a role in patients with right
bundle branch block. Circ Arrhythm Electrophysiol
2014;7:532–42.
17. Fantoni C, Kawabata M, Massaro R, et al. Right
and left ventricular activation sequence in patients
with heart failure and right bundle branch block: a
detailed analysis using three-dimensional non-
ﬂuoroscopic electroanatomic mapping system.
J Cardiovasc Electrophysiol 2005;16:112–9.
18. Hara H, Oyenuga OA, Tanaka H, et al. The
relationship of QRS morphology and mechanical
dyssynchrony to long-term outcome following
cardiac resynchronization therapy. Eur Heart J
2012;33:2680–91.
19. Vernooy K, vanDeursen CJ, StrikM, Prinzen FW.
Strategies to improve cardiac resynchronization
therapy. Nat Rev Cardiol 2014;11:481–93.
20. Gold MR, Singh JP, Ellenbogen KA, et al.
Interventricular electrical delay is predictive of
response to cardiac resynchronization therapy.
J Am Coll Cardiol EP 2016;2:438–47.
21. Auricchio A, Fantoni C, Regoli F, et al. Char-
acterization of left ventricular activation in pa-
tients with heart failure and left bundle-branch
block. Circulation 2004;109:1133–9.
22. Ploux S, Lumens J, Whinnett Z, et al. Nonin-
vasive electrocardiographic mapping to improve
patient selection for cardiac resynchronization
therapy: beyond QRS duration and left bundle
branch block morphology. J Am Coll Cardiol 2013;
61:2435–43.
23. Cluitmans MJM, Bonizzi P, Karel J, et al. In vivo
validation of electrocardiographic imaging: evalu-
ation of noninvasively reconstructed epicardial
potentials, electrograms and isochrones. J Am Coll
Cardiol EP 2017;3:232–42.
24. Johnson WB, Vatterott PJ, et al. Body surface
mapping using an ECG belt to characterize elec-
trical heterogeneity for different left ventricular
pacing sites during cardiac resynchronization:
relationship with acute hemodynamic improve-
ment. Heart Rhythm 2017;14:385–91.
25. Engels EB, Vegh EM, van Deursen CJM,
Vernooy K, Singh JP, Prinzen FW. T-wave area as
an additional predictor of response to cardiac
resynchronization therapy. J Cardiovasc Electro-
cardiol 2015;26:176–83.
26. Maﬁ Rad M, Gilbert WM, Wijntjens GMW, et al.
Vectorcardiographic QRS area identiﬁes delayed
left ventricular lateral wall activation determined
by electroanatomic mapping in patients undergo-
ing cardiac resynchronization therapy. Heart
Rhythm 2016;13:217–25.
27. Maass AH, Vernooy K, Wijers SC, et al. Reﬁning
success of cardiac resynchronization therapy using
a simple score predicting the amount of reverse
ventricular remodelling: results from the Markers
and Response to CRT (MARC) study. Europace
2017 Feb 27 [E-pub ahead of print].
28. Tereshchenko LG, Cheng A, Park J, et al.,
SMART-AV Trial Investigators. Novel measure of
electrical dyssynchrony predicts response in car-
diac resynchronization therapy: results from the
SMART-AV Trial. Heart Rhythm 2015;12:2402–10.
29. Stankovic I, Prinz C, Ciarka A, et al. Long-term
outcome after CRT in the presence of mechanical
dyssynchrony seen with chronic RV pacing or
intrinsic LBBB. J Am Coll Cardiol Img 2017;10:
1091–9.
30. Ruschitzka F, Abraham WT, Singh JP, et al.,
EchoCRT Study Group. Cardiac-resynchronization
therapy in heart failure with a narrow QRS com-
plex. N Engl J Med 2013;369:1395–405.
31. Bax JJ, Delgado V, Sogaard P, et al. Prognostic
implications of left ventricular global longitudinal
strain in heart failure patients with narrow QRS
complex treated with cardiac resynchronization
therapy: a subanalysis of the randomized EchoCRT
trial. Eur Heart J 2017;38:720–6.
32. Risum N, Tayal B, Hansen TF, et al. Identiﬁ-
cation of typical left bundle branch block
contraction by strain echocardiography is additive
to electrocardiography in prediction of long-term
outcome after cardiac resynchronization therapy.
J Am Coll Cardiol 2015;66:631–41.
33. Lumens J, Leenders GE, Cramer MJ, et al.
Mechanistic evaluation of echocardiographic dys-
synchrony indices: patient data combined with
multiscale computer simulations. Circ Cardiovasc
Img 2012;5:491–9.
34. Leenders GE, Lumens J, Cramer MJ, et al.
Septal deformation patterns delineate mechanical
dyssynchrony and regional differences in
contractility: analysis of patient data using a
computer model. Circ Heart Fail 2012;5:87–96.
35. Lumens J, Tayal B, Walmsley J, et al. Differ-
entiating the electromechanical substrate
responsive to cardiac resynchronization therapy
from non-electrical dyssynchrony substrates by
computer-assisted regional strain analysis. Circ
Cardiovasc Imag 2015;8:e003744.
36. Saba S, Marek J, Schwartzman D, Jain S,
Adelstein E, White P. Echocardiography-guided
left ventricular lead placement for cardiac
resynchronization therapy: results of the Speckle
Tracking Assisted Resynchronization Therapy for
Electrode Region trial. Circ Heart Fail 2013;6:
427–34.
37. Kydd AC, Khan FZ, Watson WD, Pugh PJ,
Virdee MS, Dutka DP. Prognostic beneﬁt of opti-
mum left ventricular lead position in cardiac
resynchronization therapy: follow-up of the
TARGET Study Cohort (Targeted Left Ventricular
Lead Placement to guide Cardiac Resynchroniza-
tion Therapy). J Am Coll Cardiol HF 2014;2:
205–12.
38. Leyva F, Foley PW, Chalil S, et al. Cardiac
resynchronisation therapy guided by late
gadolinium-enhancement cardiovascular magnetic
resonance. J Cardiovasc Magn Reson 2011;13:29.
39. Bakos Z, Ostenfeld E, Markstad H, et al.
A comparison between radial strain evaluation by
speckle-tracking echocardiography and cardiac
magnetic resonance imaging, for assessment of
suitable segments for left ventricular lead place-
ment in cardiac resynchronization therapy. Euro-
pace 2014;16:1779–86.
40. Behar J, Mountney P, Toth D, et al. Real time
X-MRI guided left ventricular lead implantation for
targeted delivery of cardiac resynchronization
therapy. J Am Coll Cardiol EP 2017;3:803–14.
41. Providencia R, Rogers D, Papageorgiou N,
et al. Long-term results of triventricular versus
biventricular pacing in heart failure: a propensity
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 3 , N O . 1 1 , 2 0 1 7 Auricchio and Prinzen
N O V E M B E R 2 0 1 7 : 1 2 0 3 – 1 9 The 3B Perspective in CRT
1217
matched comparison. J Am Coll Cardiol EP 2016;2:
825–35.
42. Leclercq C, Gadler F, Kranig W, et al.
A randomized comparison of triple-site versus
dual-site ventricular stimulation in patients with
congestive heart failure. J Am Coll Cardiol 2008;
51:1455–62.
43. Lenarczyk R, Kowalski O, Kukulski T, et al.
Midterm outcomes of triple-site vs. conventional
cardiac resynchronization therapy: a preliminary
study. Int J Cardiol 2009;133:87–94.
44. Rogers DP, Lambiase PD, Lowe MD, Chow AW.
A randomized double-blind crossover trial of
triventricular versus biventricular pacing in heart
failure. Eur J Heart Fail 2012;14:495–505.
45. Ogano M, Iwasaki YK, Tanabe J, et al. Antiar-
rhythmic effect of cardiac resynchronization
therapy with triple-site biventricular stimulation.
Europace 2013;15:1491–8.
46. Forleo GB, Di Biase L, Bharmi R, et al. Hospi-
talization rates and associated cost analysis of
cardiac resynchronization therapy with an
implantable deﬁbrillator and quadripolar vs. bi-
polar left ventricular leads: a comparative effec-
tiveness study. Europace 2015;17:101–7.
47. Turakhia MP, Cao M, Fischer A, et al. Reduced
mortality associated with quadripolar compared to
bipolar left ventricular leads in cardiac resynch-
ronization therapy. J Am Coll Cardiol EP 2016;2:
426–33.
48. Pappone C, Calovic Z, Vicedomini G, et al.
Multipoint left ventricular pacing improves
acute hemodynamic response assessed with
pressure-volume loops in cardiac resynchroniza-
tion therapy patients. Heart Rhythm 2014;11:
394–401.
49. Zanon F, Baracca E, Pastore G, et al. Multi-
point pacing by a left ventricular quadripolar lead
improves the acute hemodynamic response to CRT
compared with conventional biventricular pacing
at any site. Heart Rhythm 2015;12:975–81.
50. Pappone C, Calovic Z, Vicedomini G, et al.
Improving cardiac resynchronization therapy
response with multipoint left ventricular pacing:
twelve-month follow-up study. Heart Rhythm
2015;12:1250–8.
51. Zanon F, Marcantoni L, Baracca E, et al. Opti-
mization of left ventricular pacing site plus mul-
tipoint pacing improves remodeling and clinical
response to cardiac resynchronization therapy at 1
year. Heart Rhythm 2016;13:1644–51.
52. St. Jude Medical. St. Jude Medical announces
MultiPoint Pacing IDE study results during late-
Breaker at Heart Rhythm 2016. Available at:
http://media.sjm.com/newsroom/news-releases/
news-releases-details/2016/St-Jude-Medical-
Announces-MultiPoint-Pacing-IDE-Study-Results-
During-Late-Breaker-at-Heart-Rhythm-2016/default.
aspx. Accessed June 3, 2017.
53. Sterlinski M, Sokal A, Lenarczyk R, et al. In
heart failure patients with left bundle branch
block single lead multispot left ventricular pacing
does not improve acute hemodynamic response to
conventional biventricular pacing. A multicenter
prospective, interventional, non-randomized
study. PLoS One 2016;11:e0154024.
54. Hyde ER, Behar JM, Claridge S, et al. Beneﬁcial
effect on cardiac resynchronization from left
ventricular endocardial pacing is mediated by early
access to high conduction velocity tissue: elec-
trophysiological simulation study. Circ Arrhythm
Electrophysiol 2015;8:1164–72.
55. Strik M, van Middendorp LB, Vernooy K. Ani-
mal models of dyssynchrony. J Cardiovasc Transl
Res 2012;5:135–45.
56. Van Deursen C, Van Geldorp I,
Rademakers LM, et al. Left ventricular endocardial
pacing improves resynchronization therapy in
canine LBBB hearts. Circ Arrhyth Electrophysiol
2009;2:580–7.
57. Derval N, Steendijk P, Gula LJ, et al. Opti-
mizing hemodynamics in heart failure patients by
systematic screening of left ventricular pacing
sites: the lateral left ventricular wall and the
coronary sinus are rarely the best sites. J Am Coll
Cardiol 2010;55:566–75.
58. Spragg DD, Dong J, Fetics BJ, et al. Optimal
left ventricular endocardial pacing sites for cardiac
resynchronization therapy in patients with
ischemic cardiomyopathy. J Am Coll Cardiol 2010;
56:774–81.
59. Shetty AK, Sohal M, Chen Z, et al.
A comparison of left ventricular endocardial,
multisite, and multipolar epicardial cardiac
resynchronization: an acute haemodynamic and
electroanatomical study. Europace 2014;16:
873–9.
60. Morgan JM, Bifﬁ M, Gellér L, et al.,
ALSYNC Investigators. ALternate Site Cardiac
ResYNChronization (ALSYNC): a prospective and
multicentre study of left ventricular endocardial
pacing for cardiac resynchronization therapy. Eur
Heart J 2016;37:2118–27.
61. Auricchio A, Delnoy PP, Butter C, et al., for the
Collaborative Study Group. Feasibility, safety, and
short-term outcome of leadless ultrasound-based
endocardial left ventricular resynchronization in
heart failure patients: results of the Wireless
Stimulation Endocardially for CRT (WiSE-CRT)
study. Europace 2014;16:681–8.
62. Narula OS. Longitudinal dissociation in the His
bundle. Bundle branch block due to asynchronous
conduction within the His bundle in man. Circula-
tion 1977;56:996–1006.
63. Upadhyay GA, Tung R. Selective versus non-
selective His bundle pacing for cardiac resynch-
ronization therapy. J Electrocardiol 2017;50:
191–4.
64. Sharma PS, Ellenbogen KA, Trohman RG.
Permanent His bundle pacing: the past, present,
and future. J Cardiovasc Electrophysiol 2017;28:
458–65.
65. Teng AE, Lustgarten DL, Vijayaraman P, et al.
Usefulness of His bundle pacing to achieve elec-
trical resynchronization in patients with complete
left bundle branch block and the relation between
native QRS axis, duration, and normalization. Am J
Cardiol 2016;118:527–34.
66. Ajijola OA, Upadhyay G, Macias C,
Shivkumar K, Tung R. Permanent His-bundle pac-
ing for cardiac resynchronization therapy: initial
feasibility study in lieu of left ventricular lead.
Heart Rhythm 2017;14:1353–61.
67. Mills RW, Cornelussen RN, Mulligan LJ, et al.
Left ventricular septal and left ventricular apical
pacing chronically maintain cardiac contractile
coordination, pump function and efﬁciency. Circ
Arrhyth Electrophysiol 2009;2:571–9.
68. Maﬁ-Rad M, Luermans JGLM, Blaauw Y, et al.
Feasibility and acute hemodynamic effect of left
ventricular septal pacing by transvenous approach
through the interventricular septum. Circ
Arrhythm Electrophysiol 2016;9:e003344.
69. Rademakers LM, van Hunnik A, Kuiper M, et al.
A possible role for pacing the LV septum in cardiac
resynchronization therapy. J Am Coll Cardiol EP
2016;2:413–22.
70. AbrahamWT,GrasD, YuCM,GuzzoL,GuptaMS,
FREEDOM Steering Committee. Rationale and
design of a randomized clinical trial to assess the
safety and efﬁcacy of frequent optimization of car-
diac resynchronization therapy: the Frequent Opti-
mization Study Using the QuickOpt Method
(FREEDOM) trial. Am Heart J 2010;159:944–8.
71. Ellenbogen KA, Gold MR, Meyer TE, et al.
Primary results from the SmartDelay determined
AV optimization: a comparison to other AV delay
methods used in cardiac resynchronization therapy
(SMART-AV) trial: a randomized trial comparing
empirical, echocardiography-guided, and algo-
rithmic atrioventricular delay programming in
cardiac resynchronization therapy. Circulation
2010;122:2660–8.
72. BrugadaJ,DelnoyPP,BrachmannJ,etal., for the
RESPOND CRT Investigators. Contractility sensor-
guided optimization of cardiac resynchronization
therapy: results from the RESPOND-CRT trial. Eur
Heart J 2017;38:730–8.
73. Singh JP, AbrahamWT, Chung ES, et al. Clinical
response with adaptive CRT algorithm compared
with CRT with echocardiography-optimized atrio-
ventricular delay: a retrospective analysis of mul-
ticentre trials. Europace 2013;15:1622–8.
74. Martin DO, Lemke B, Birnie D, et al., Adaptive
CRT Study Investigators. Investigation of a novel
algorithm for synchronized left-ventricular pacing
and ambulatory optimization of cardiac resynch-
ronization therapy: results of the adaptive CRT
trial. Heart Rhythm 2012;9:1807–14.
75. Starling RC, Krum H, Bril S, et al. Impact of a
novel adaptive optimization algorithm on 30-day
readmissions: evidence from the Adaptive CRT
Trial. J Am Coll Cardiol HF 2015;3:565–72.
76. Engels EB, Strik M, van Middendorp LB,
Kuiper M, Vernooy K, Prinzen FW. Prediction of
optimal cardiac resynchronization by vectors
extracted from electrograms in dyssynchronous
canine heart. J Cardiovasc Electrophys 2017;28:
944–51.
77. van Deursen CJM, Vernooy K, Dudink E, et al.
Vectorcardiographic parameters as novel pre-
dictors of response to cardiac resynchronization
therapy. J Electrocardiogr 2015;48:45–52.
78. Kutyifa V, Pouleur AC, Knappe D, et al. Dys-
synchrony and the risk of ventricular arrhythmias.
J Am Coll Cardiol Img 2013;6:432–44.
79. Tayal B, Gorcsan J 3rd, Delgado-Montero A,
et al. Mechanical dyssynchrony by tissue Doppler
cross-correlation is associated with risk for com-
plex ventricular arrhythmias after cardiac
Auricchio and Prinzen J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 3 , N O . 1 1 , 2 0 1 7
The 3B Perspective in CRT N O V E M B E R 2 0 1 7 : 1 2 0 3 – 1 9
1218
resynchronization therapy. J Am Soc Echocardiogr
2015;28:1474–81.
80. Avicenna Roadmap: In Silico Clinical Trials.
Available at: http://avicenna-alliance.com/
avicenna-roadmap/. Accessed October 30, 2017.
81. Lumens J, Delhaas T, Kirn B, Arts T. Three-wall
segment (TriSeg) model describing mechanics and
hemodynamics of ventricular interaction. Ann
Biomed Eng 2009;37:2234–55.
82. Niederer SA, Lamata P, Plank G, et al.
Analyses of the redistribution of work
following cardiac resynchronisation therapy in
a patient speciﬁc model. PLoS One 2012;7:
e43504.
83. Panthee N, Okada J, Washio T, et al. Tailor-
made heart simulation predicts the effect of
cardiac resynchronization therapy in a canine
model of heart failure. Med Image Anal 2016;31:
46–62.
84. Sermesant M, Chabiniok R, Chinchapatnam P,
et al. Patient-speciﬁc electromechanical models of
the heart for the prediction of pacing acute effects
in CRT: a preliminary clinical validation. Med Image
Anal 2012;16:201–15.
85. Potse M, Krause D, Kroon W, et al. Patient-
speciﬁc modeling of cardiac electrophysiology in
heart-failure patients. Europace 2014;4:iv56–61.
86. Remme EW, Niederer S, Gjesdal O, et al.
Factors determining the magnitude of the pre-
ejection leftward septal motion in left bundle
branch block. Europace 2016;18:1905–13.
87. Walmsley J, Huntjens PR, Prinzen FW,
Delhaas T, Lumens J. Septal ﬂash and septal
rebound stretch have different underlying mech-
anisms. Am J Physiol 2016;310:H394–403.
88. Kroon W, Lumens J, Potse M, et al. In vivo
electromechanical assessment of heart failure
patients with prolonged QRS duration. Heart
Rhythm 2015;12:1259–67.
89. Villongco CT, Krummen DE, Omens JH,
McCulloch AD. Non-invasive, model-based mea-
sures of ventricular electrical dyssynchrony for
predicting CRT outcomes. Europace 2016;18 Suppl
4:iv104–12.
90. Crozier A, Blazevic B, Lamata P, et al. The
relative role of patient physiology and device
optimisation in cardiac resynchronisation therapy:
a computational modelling study. J Mol Cell
Cardiol 2016;96:93–100.
91. Niederer SA, Shetty AK, Plank G, Bostock J,
Razavi R, Smith NP, Rinaldi CA. Biophysical
modeling to simulate the response to multisite
left ventricular stimulation using a quadripolar
pacing lead. Pacing Clin Electrophysiol 2012;35:
204–14.
KEY WORDS cardiac magnetic resonance,
cardiac resynchronization therapy, left
bundle branch block, outcome, pacing
Go to http://www.acc.
org/jacc-journals-cme to
take the CME/MOC quiz
for this article.
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 3 , N O . 1 1 , 2 0 1 7 Auricchio and Prinzen
N O V E M B E R 2 0 1 7 : 1 2 0 3 – 1 9 The 3B Perspective in CRT
1219
